Financial Performance - The company reported a net profit attributable to shareholders of -480,677,442.19 CNY for 2025, indicating a 30.01% improvement compared to -686,817,534.59 CNY in 2024[6]. - Total revenue for 2025 was 2,319,940,494.74 CNY, reflecting a 4.08% increase from 2,228,939,970.82 CNY in 2024[24]. - The basic earnings per share for 2025 was -0.64 CNY, an improvement from -0.91 CNY in 2024[25]. - The company reported a net cash flow from operating activities of -72,080,069.35 CNY, a significant improvement of 77.22% compared to -316,469,787.11 CNY in 2024[24]. - The weighted average return on equity for 2025 was -25.31%, an increase of 2.34 percentage points from -27.65% in 2024[25]. - The company reported a significant decline in net profit, with Q4 2025 showing a net loss of CNY -169,555,719.82[27]. - The company achieved a revenue of 2.32 billion RMB, representing a year-on-year growth of 4.08% from 2.23 billion RMB[51]. - The net profit attributable to shareholders was -480 million RMB, an improvement of 30.01% compared to the previous year[51]. Cash Flow and Dividends - The company has cumulative undistributed losses of 231,496,492.99 CNY, which affects its ability to distribute dividends[7]. - The company plans not to distribute profits or increase capital reserves due to the negative net profit for 2025[6]. - The cash dividend policy remains unchanged, with a commitment to distribute at least 20% of the annual distributable profits in cash[142]. - The company reported a net profit attributable to shareholders of the parent company as negative, with cumulative undistributed losses, thus no cash dividends will be distributed for the fiscal year 2025[143]. - The company has not proposed any cash profit distribution plan despite having positive distributable profits for the parent company during the reporting period[145]. - The company has not conducted any cash dividends or share buybacks in the last three accounting years, with a total cash dividend amount of 0 RMB[146]. Operational Overview - The company operates seven retail stores in Beijing, with a total area of 402,300 square meters, primarily focusing on department and supermarket formats[35]. - The revenue from the company's retail business is mainly derived from merchandise sales and leasing income[35]. - The company is focusing on optimizing its product and service structure to enhance digital retail scenarios and improve operational efficiency[36]. - The company is actively exploring AI technology applications in commercial scenarios, enhancing its "AI Smart Shopping" system[47]. - The company is committed to a strategic focus on "commercial + technology" development, aiming to create a comprehensive urban commercial service enterprise[95]. Market and Industry Trends - The company faces various risks including economic, industry, market, and operational risks as detailed in the management discussion section[10]. - The total retail sales of social consumer goods in China are expected to exceed 50 trillion yuan, growing by 3.7% year-on-year in 2025[41]. - The online retail sales are projected to grow by 8.6%, with physical goods online retail sales reaching 13.0923 trillion yuan, a year-on-year increase of 5.2%[41]. - The retail market continues to face pressure with declining transaction volumes and increased competition, prompting the company to adapt its strategies for store transformation and online marketing[102]. Investment and Development - The company plans to invest a total of 200 million yuan in the urban renewal project of the Contemporary Mall in Zhongguancun by the end of 2025[36]. - The company plans to accelerate urban renewal projects with an annual fixed asset investment of 237 million yuan, focusing on quality, safety, and cost control[97]. - The company invested 500 million yuan to establish the Suzhou Cuiwei New Life Equity Investment Fund, with a total contribution of 1 billion yuan, focusing on consumption upgrades and health-related sectors[85]. - The company also invested 600 million yuan to set up the Beijing Rongzhi Cuiwei Lantian Equity Investment Fund, increasing the total contribution to 750 million yuan, targeting clean energy and technology innovation[86]. Governance and Compliance - The company has established a governance structure that includes a board of directors and specialized committees to enhance decision-making efficiency and risk control[107]. - The company has completed the revision of 377 governance documents in compliance with new legal and regulatory requirements[48]. - The audit committee confirmed that the 2024 annual report complies with the relevant regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange[130]. - The company has established measures to ensure that its operations remain independent from those of its controlling entities[161]. Employee and Training Initiatives - The company has a total of 1,760 employees, with 951 in the parent company and 809 in major subsidiaries[137]. - In 2025, the company organized over 80 training sessions with more than 4,600 participants, enhancing employee skills and engagement[140]. - The company plans to implement a tiered training system in 2026, focusing on core business and key technologies to improve talent development[141]. Social Responsibility - The company has actively engaged in social responsibility initiatives, contributing a total of 64,200 RMB to various charitable activities in 2025[154]. - The company has signed long-term green electricity trading agreements to reduce future electricity costs for its properties[151]. - Total investment in poverty alleviation and rural revitalization projects amounted to 140,000 RMB, with 14,000 RMB allocated as funds[156]. - The company purchased over 3,000 agricultural products from Sujiatuo and Danjiangkou, totaling 140,000 RMB in support of consumption poverty alleviation policies[157].

Financial Performance - The company's operating revenue for 2025 reached ¥6,168,036,314.63, representing a 2.26% increase from ¥6,031,865,460.16 in 2024[21] - Total profit for 2025 was ¥1,822,723,792.40, a decrease of 28.44% compared to ¥2,547,217,502.79 in 2024[21] - Net profit attributable to shareholders for 2025 was ¥1,090,837,981.20, down 29.59% from ¥1,549,164,832.24 in 2024[21] - The net cash flow from operating activities for 2025 was ¥338,746,658.63, a significant decline of 58.68% from ¥819,780,705.09 in 2024[21] - Basic earnings per share for 2025 were ¥0.55, a decrease of 29.59% from ¥0.78 in 2024[22] - The weighted average return on net assets for 2025 was 9.51%, down 5.30 percentage points from 14.81% in 2024[23] Dividend Distribution - The company plans to distribute a cash dividend of ¥0.05 per share, totaling ¥395,474,289.20, which accounts for 36.25% of the net profit attributable to shareholders[4] - The company does not have any unremedied losses affecting dividend distribution[5] - The proposed cash dividend for the year 2024 is CNY 0.1 per share, totaling CNY 197,737,144.60, based on a total share capital of 1,977,371,446 shares[184] - The cash dividend for the first half of 2025 is set at CNY 0.15 per share, amounting to CNY 296,605,716.90, which represents 46.89% of the net profit attributable to shareholders for that period[185] - The total cash dividend for 2025, including the mid-year distribution, is CNY 395,474,289.20, accounting for 36.25% of the net profit attributable to shareholders[186] - The cumulative cash dividend over the last three accounting years is CNY 840,382,864.50, with an average annual net profit of CNY 1,249,963,803.55, resulting in a cash dividend ratio of 67.23%[190][191] Revenue Breakdown - The company's total revenue for Q1 was approximately CNY 1.32 billion, Q2 was CNY 1.79 billion, Q3 was CNY 1.35 billion, and Q4 was CNY 1.70 billion[24] - The revenue from immunoglobulin products was ¥3,078,732,221.58, achieving a gross margin of 48.01%, which is an increase of 11.64% in revenue year-over-year and an improvement of 34.80% in gross margin percentage[91] - The sales revenue from human blood products was ¥2,441,905,756.70, with a gross margin of 39.47%, showing a decline of 2.71% in revenue compared to the previous year and a decrease of 11.73% in gross margin percentage[91] - The company's revenue from the biological products sector reached ¥6,149,036,539.41, with a gross margin of 43.75%, reflecting a year-over-year increase of 2.27% in revenue but a decrease of 10.92% in gross margin percentage[91] Research and Development - The company’s R&D expenses increased by 12.05% to CNY 159.99 million, reflecting the progress of ongoing projects[88] - The company has developed a comprehensive R&D pipeline focusing on high-concentration immunoglobulin and recombinant coagulation factors, maintaining a leading position in the domestic industry[77] - The company is actively investing in R&D, focusing on enhancing product variety and quality, with a commitment to high-level R&D input and talent acquisition[113] - The company reported a significant increase in R&D investment, with a total of ¥39,834,185.22 allocated to the development of recombinant coagulation factor VIII, representing 0.65% of operating revenue[118] - The company’s R&D investment in the clinical study of intravenous human immunoglobulin increased by 87.52%, reflecting its commitment to advancing treatment options[119] Market Presence and Operations - The company has a total of 107 plasma collection stations across 16 provinces/regions in China, with 85 operational stations collecting 2,801 tons of plasma, maintaining approximately 20% market share in the industry[42] - The company operates over 1,000 hospitals across more than 30 provincial-level administrative regions, ensuring a leading position in terminal coverage[84] - The company has expanded its market coverage to over 1,000 hospitals at the tertiary level across more than 30 provincial administrative regions in China[67] - The company has a strong focus on expanding its market presence and enhancing its core competitiveness through quality improvement and technological advancements[41] Compliance and Governance - The company adheres to strict information disclosure regulations to ensure transparency and protect the rights of all shareholders, especially minority shareholders[153] - The company has established a governance framework to enhance oversight of key areas and ensure compliance in subsidiary operations[12] - The company has implemented a performance evaluation system for senior management to enhance operational efficiency and accountability[152] - The company has established a strong governance structure with independent directors contributing to oversight and compliance[157] Challenges and Risks - The blood products industry is facing short-term challenges due to tightened medical insurance controls and price declines, with inventory levels rising significantly[131] - Rising material and labor costs, along with increased competition from imported human albumin, pose a risk of declining gross margins for blood products[147] - The supply of raw materials, specifically human plasma, is tightening as the government imposes stricter controls on new plasma collection stations, potentially leading to supply shortages[146] - The development of new blood products and recombinant coagulation factors involves high risks and long development cycles, with potential market demand not meeting expectations[148] Corporate Social Responsibility - The company made a total investment of 750.84 million yuan in public welfare donations, with 748 million yuan in cash donations and 2.84 million yuan in material donations[198] - The company participated in poverty alleviation and rural revitalization projects with a total investment of 72.93 million yuan, benefiting 19 counties across 10 provinces[198] - The company has disclosed its ESG report for the year 2025, highlighting its commitment to social responsibility and sustainable development[197]

烟台北方安德利果汁股份有限公司 2025 年年度报告 公司代码：605198 公司简称：安德利 烟台北方安德利果汁股份有限公司 2025 年年度报告 1 / 157 烟台北方安德利果汁股份有限公司 2025 年年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证年度报告内容的真实性、准确性、完整性，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 致同会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人王安、主管会计工作负责人王艳辉及会计机构负责人（会计主管人员）李磊声明： 保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司采用现金分红方式，以目前股本总数334,188,000股为基数，向全体股东每十股派发现金红利 人民币3.00元(含税)，派发现金红利总额为人民币100,256,400.00元，占2025年度合并报表归属 于母公司普通股股东净利润的30.35%，剩余未分配利润结转以后年度分配。现金红利以人民币计 值和宣布，以人民币向A股股东支 ...

广州市广百股份有限公司 2025 年年度报告全文 广州市广百股份有限公司 2025 年年度报告 【2026 年 3 月】 1 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 广州市广百股份有限公司 2025 年年度报告全文 2025 年年度报告 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责 任。 公司负责人康永平、主管会计工作负责人王玟及会计机构负责人（会计 主管人员）曹细妹声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承 诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、 预测与承诺之间的差异。 本报告第三节"管理层讨论与分析"中"十一、公司未来发展的展望" 详细描述了公司经营中可能存在的风险及应对措施，敬请投资者关注相关内 容。 | | | 广州市广百股份有限公司 2025 年年度报告全文 备查文件目录 一、载有公司负责人、主管会计工作负责人、会计机构负 ...

Financial Performance - The company's operating revenue for 2025 reached ¥1,131,246,944.93, representing a 7.66% increase compared to ¥1,050,736,998.28 in 2024[23] - The total profit for 2025 was ¥27,569,054.89, which is a 33.85% increase from ¥20,597,395.74 in 2024[23] - The net profit attributable to shareholders for 2025 was ¥24,552,718.70, up 33.24% from ¥18,427,900.30 in 2024[23] - The basic earnings per share for 2025 was ¥0.112, reflecting a 33.33% increase from ¥0.084 in 2024[24] - The total assets at the end of 2025 amounted to ¥1,154,403,976.36, an 11.95% increase from ¥1,031,205,356.64 in 2024[23] - The net cash flow from operating activities for 2025 was ¥126,612,952.37, a 7.87% increase compared to ¥117,379,128.09 in 2024[23] - The total comprehensive income rose by 36.37% to ¥26,208,802.23 from ¥19,218,614.64 year-on-year[69] - The debt-to-asset ratio was 52.67%, an increase of 3.57 percentage points from the previous year[64] Revenue Breakdown - The agricultural machinery segment generated revenue of 283.72 million yuan, marking a 26.77% increase compared to the previous year[48] - The special vehicles segment reported revenue of 467.21 million yuan, a growth of 20.6% year-on-year[51] - Motorcycle revenue reached 125.34 million yuan, showing a significant increase of 35.7%[51] - The cumulative sales of tracked self-propelled combine harvesters in 2025 reached 60,500 units, a 15.87% increase from 2024[41] - Revenue from the special vehicles sector was ¥467,207,688.51, with a gross margin of 15.27%, a decrease of 0.82 percentage points year-on-year[78] - Revenue from the agricultural machinery sector was ¥283,722,402.61, with a gross margin of 7.14%, down by 1.92 percentage points year-on-year[78] - Revenue from the motorcycle sector increased by 35.70% to ¥125,340,298.09, with a gross margin of 10.34%, an increase of 9.13 percentage points year-on-year[78] Research and Development - The company obtained 12 authorized patents in 2025, including 6 invention patents, enhancing its core technology barriers[53] - The company has a strong research and development team, including 3 experts receiving government special allowances and 56 senior professionals[60] - Total R&D expenditure for the period was CNY 45,742,943.50, representing 4.04% of total revenue[90] - Research and development expenses increased by 25%, amounting to 150 million RMB, focusing on innovative technologies[134] Market and Industry Insights - The company operates in the forest fire-fighting machinery, agricultural machinery, all-terrain vehicles, and motorcycle industries, focusing on the forest fire-fighting machinery segment[32] - The forest fire-fighting machinery industry is expected to grow due to increasing global forest fire incidents and government emphasis on advanced technology and equipment[39] - The all-terrain vehicle product line has achieved advanced performance metrics, including speed and power, and is marketed in regions such as the US, EU, and Southeast Asia[39] - The company’s market structure is increasingly diversified, with international and domestic sales accounting for 51.47% and 48.53% respectively[44] Cost Management and Efficiency - The company has developed a comprehensive cost control model, enhancing the cost-effectiveness of its main products[61] - The company optimized its supply chain by introducing 11 new suppliers, leading to a decrease in key material procurement costs[57] - The company has implemented measures to control costs through price locking, phased purchasing, and value chain optimization in response to raw material price volatility[123] - The company is exploring potential acquisitions to enhance its supply chain efficiency, with a budget of 300 million RMB allocated for this purpose[134] Risk Management - The company anticipates macroeconomic risks due to global economic slowdown and geopolitical tensions, and plans to explore dual circulation and digital development strategies to mitigate these risks[119] - The company faces market competition risks influenced by international geopolitical conflicts and trade protectionism, and will focus on product competitiveness and innovation to address these challenges[120] - The company is exposed to exchange rate risks due to its increasing overseas business, and will implement measures such as timely settlement and forward foreign exchange contracts to minimize potential losses[122] - The company is focused on risk management, implementing a comprehensive risk control system to monitor and mitigate key risks effectively[118] Governance and Compliance - The internal control system is operating effectively, with no significant defects in financial or non-financial reporting identified for the year[128] - The company has revised 15 internal regulations and established five new systems to enhance governance and operational efficiency[127] - The company emphasizes compliance with information disclosure regulations, ensuring transparency and accuracy in communications with investors[130] - The audit report confirms that the financial statements fairly reflect the company's financial position as of December 31, 2025[198] Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 12,332, a decrease from 12,821 at the end of the previous month[184] - The largest shareholder, China Fuma Machinery Group Co., Ltd., holds 92,256,920 shares, representing 42.10% of the total shares, with 46,128,420 shares pledged[188] - The second-largest shareholder, Zhou Yuguang, holds 7,740,518 shares, accounting for 3.53% of the total shares[188] - The company has not disclosed any significant changes in its share capital structure during the reporting period[183] Employee and Management Insights - The total number of employees in the parent company and major subsidiaries is 660, with 389 in production roles and 151 in technical positions[149][150] - The company has implemented a salary increase policy for 2025 to attract high-level graduates from "985" universities and improve compensation for young technical staff[151] - The total compensation for non-independent directors and senior management during the reporting period was CNY 3.4176 million[139] - The company’s senior management compensation includes a deferred payment arrangement based on performance[139]

华峰化学股份有限公司 2025 年年度报告 2026 年 3 月 华峰化学股份有限公司 2025 年年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完整，不存在虚假记载、误导 性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人尤飞煌、主管会计工作负责人孙洁及会计机构负责人（会计主管人员）孙洁声明：保证 本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 如本报告中涉及未来计划等前瞻性陈述，不构成公司对投资者的实质性承诺，投资者及相关人士均 应当对此保持足够的风险认识，并且应当理解计划、预测与承诺之间的差异。除公司整体面临的宏观经 济波动风险、市场竞争及营业利润波动风险等风险外，公司存在市场变化、行业周期变动以及原材料价 格波动等风险，敬请广大投资者注意投资风险。 本年度报告中所涉及未来的经营计划和经营目标并不代表公司对未来的盈利预测，公司存在市场变 化、行业周期变动以及原材料价格波动等风险，敬请广大投资者注意投资风险。 公司经本次董事会审议通过的利润分配预案为：以 4,962,543,897.00 为基数，向全体 ...

Financial Performance - The company's operating revenue for 2025 reached ¥15,358,190,328.79, representing a 26.18% increase compared to ¥12,172,087,561.40 in 2024[35]. - Total profit for 2025 was ¥6,644,139,996.68, an increase of 81.57% from ¥3,659,254,017.87 in 2024[35]. - Net profit attributable to shareholders for 2025 was ¥5,633,559,541.41, up 68.16% from ¥3,350,208,782.40 in 2024[35]. - The company's net profit for 2025 reached CNY 5,633,651,831.14, representing a 68.15% increase compared to CNY 3,350,447,340.65 in 2024[50]. - Operating revenue for 2025 was CNY 15,358,190,328.79, up 26.18% from CNY 12,172,087,561.40 in 2024[50]. - The company's total assets reached RMB 486.88 billion, an increase of 16.55% compared to the previous year[112]. - Net profit attributable to shareholders was RMB 5.63 billion, a year-on-year increase of 68.16%[112]. - Operating revenue amounted to RMB 15.36 billion, reflecting a growth of 26.18% year-on-year[114]. Dividend Distribution - The annual profit distribution plan for 2025 proposes a cash dividend of RMB 2.00 per 10 shares, totaling RMB 1.687 billion, which accounts for 29.95% of the net profit attributable to the parent company[6]. - The total cash dividends for 2025, including the mid-year distribution, amount to RMB 2.699 billion, representing 47.91% of the net profit attributable to the parent company[6]. - The company does not have any unremedied losses that would affect its dividend distribution[8]. Risk Management - The company faces various risks including market volatility, regulatory changes, and operational risks, which could adversely affect its business performance[11][12]. - The company has implemented a comprehensive risk management system to address potential risks, including compliance, legal, and operational risks[12]. - The company maintains a strong compliance and risk management framework, achieving an A-class rating for 17 consecutive years[110]. - The company is committed to enhancing its compliance and risk management practices to prevent systemic risks and significant operational losses[174]. - The company has established a comprehensive credit risk management system, ensuring credit risk is measurable, controllable, and bearable through strict contract reviews and in-depth due diligence assessments[178]. Business Operations and Structure - The company has completed the absorption merger with Dongfang Investment Bank in September 2024, enhancing its operational capabilities[15]. - The company has established a comprehensive organizational structure, including a board of directors and various specialized committees for strategic and risk management[29]. - The company has a total of 4 wholly-owned subsidiaries in mainland China and 1 wholly-owned subsidiary in Hong Kong[31]. - The company has a total of 170 securities branches distributed across various regions, with 46 in Shanghai and 15 in Guangdong[32]. - The company has undergone several capital increases, including a public offering of 1 billion A-shares in 2015, raising its registered capital to RMB 5,281,742,921.00[28]. Asset Management and Investment - The company’s asset management business is focused on integrating public fund and securities management, driving growth in management scale and business revenue[67]. - The public fund management scale was RMB 216.29 billion, up 30.16% from the previous year, while private equity management scale grew by 48.12% to RMB 66.60 billion[69]. - The company launched several successful products, including the Dongfanghong Core Value Fund, which raised RMB 1.991 billion, and the Dongfanghong Yingfeng FOF, which raised over RMB 6.5 billion, marking the largest public fund issuance during the reporting period[68]. - The company achieved significant milestones in its asset management business, with the non-monetary public fund scale remaining in the top ten of the industry[143]. Technology and Innovation - The company is focusing on enhancing its wealth management services by integrating advanced financial technology with traditional brokerage advantages[56]. - The company launched the 6.0 version of the Dongfang Winner App, enhancing customer investment efficiency and experience through a comprehensive upgrade of services[60]. - The company has established a digital transformation plan, enhancing customer service quality through technology innovation and new business models[144]. - The company successfully upgraded its AI computing cluster and launched innovative projects such as AI-driven investment advisory services[144]. Market Position and Strategy - The company aims to enhance its investment banking services by focusing on technology innovation and energy sectors, aligning with national strategic directions[79]. - The company plans to deepen its risk management services and enhance its internationalization efforts through its Singapore subsidiary[77]. - The company aims to strengthen its international business strategy, enhancing global market coordination and product diversification[101]. - The strategic plan for 2025-2027 focuses on "grouping, digitization, and internationalization," with a development path emphasizing comprehensive wealth management and investment banking[171]. Compliance and Governance - The company has established an IT governance system with clear objectives and organizational structure to manage information technology risks effectively[187]. - The company has conducted extensive anti-money laundering training and awareness campaigns, reaching over 13,000 participants through various promotional activities[185]. - The company has established a data cross-border management guideline to comply with relevant laws and ensure proper handling of personal information[188]. - The total compliance and risk management investment amounted to RMB 301 million during the reporting period[197].

盈康生命科技股份有限公司 2025 年年度报告全文 1 盈康生命科技股份有限公司 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律 责任。 公司负责人马安捷、主管会计工作负责人江兰及会计机构负责人(会计主 管人员)侯兆坤声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告中所涉及的发展战略、经营计划等前瞻性陈述属于计划性事 项，该计划不构成公司对投资者的实质承诺，投资者及相关人士均应当对此 保持足够的风险认识，并且应当理解计划、预测与承诺之间的差异，敬请投 资者注意投资风险。 公司需遵守《深圳证券交易所上市公司自律监管指引第 4 号——创业板 行业信息披露》"第三章生物产业"之"第二节医疗器械业务"的披露要求。 请投资者注意阅读本报告第三节第十一条公司未来发展的展望章节对公司风 险提示的相关内容。 公司经本次董事会审议通过的利润分配预案为：以截至 2025 年 12 月 31 日公司总股本 749,451,604 股扣除回购专用证券账户中股份数 ...

Financial Performance - In 2025, the total operating revenue was CNY 332,994.10 million, a decrease of 30.39% compared to the previous year[4] - The net profit attributable to shareholders was CNY -64,634.23 million, an increase in loss of 2.25% year-on-year[4] - The net profit after deducting non-recurring gains and losses was CNY -77,533.15 million, an increase in loss of 11.94% year-on-year[4] - The basic earnings per share were CNY -0.58, indicating a non-applicable change compared to the previous year[4] - The weighted average return on net assets was -44.90%, a decrease of 14.45 percentage points compared to the previous year[4] Asset and Equity - The total assets at the end of the reporting period were CNY 440,503.86 million, reflecting a growth of 12.84% from the beginning of the year[6] - The equity attributable to shareholders decreased by 36.46% to CNY 112,016.91 million due to losses incurred[8] Market Conditions - The average selling price of propylene (excluding tax) was CNY 5,791.71 per ton, down 5.92% from CNY 6,155.83 per ton in 2024[7] - The gross profit margin for the main product, propylene, remained negative, contributing to the operating loss in 2025[7] - The company faced challenges due to overcapacity and weak demand in the PDH industry, exacerbated by high raw material costs from import tariffs[7]

上海徐家汇商城股份有限公司 2025 年年度报告 2026 年 03 月 | 目录 | | --- | | 第一节 | 重要提示、目录和释义 2 | | --- | --- | | 第二节 | 公司简介和主要财务指标 5 | | 第三节 | 管理层讨论与分析 9 | | 第四节 | 公司治理、环境和社会 29 | | 第五节 | 重要事项 48 | | 第六节 | 股份变动及股东情况 57 | | 第七节 | 债券相关情况 63 | | 第八节 | 财务报告 64 | 上海徐家汇商城股份有限公司 2025 年年度报告全文 第一节 重要提示、目录和释义 三、载有上会会计师事务所（特殊普通合伙）盖章、注册会计师张婕、侯 月婷签名并盖章的公司 2025 年度审计报告原件。 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责 任。 公司负责人韩军、主管会计工作负责人庞维聆及会计机构负责人（会计主 管人员）袁思贤声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 1、可能存在消费需求下降、营运成本 ...